ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody Hot |Claudin 18.2 |Cadherin-17
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > IL-6

IL-6

概要

Name:Interleukin-6
Target Synonym:CTL Differentiation Factor,Interleukin 6 (Interferon, Beta 2),HSF,B-cell stimulatory factor 2,Interferon beta-2,IL6,IFNB2,IL-6,Interleukin-6,Interleukin 6,Hybridoma Growth Factor,IFN-Beta-2,BSF-2,CDF,B-Cell Differentiation Factor,Interferon, Beta 2,Interleukin BSF-2,BSF2,HGF
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
GMP-L06H27 Human GMP Human IL-6 Protein
GMP-L06H27-structure
GMP-L06H27-sds
IL6-Y65 Mouse Mouse IL-6 Antibody, Mouse IgG1 (1A11E2)
CRS-B001 Human ClinMax™ Human IL-6 ELISA Kit
EP-146 Human IL-6[Biotinylated] : IL-6 R alpha Inhibitor Screening ELISA Kit
IL6-C5249 Cynomolgus Cynomolgus IL-6 Protein, His Tag (MALS verified)
IL6-C5249-structure
IL6-C5249-sds
IL6-H82Q9 Human Biotinylated Human IL-6 Protein, Avitag™,His Tag
IL6-H82Q9-structure
IL6-H82Q9-sds
IL6-M82Q7 Mouse Biotinylated Mouse IL-6 Protein, Avitag™,His Tag
IL6-M82Q7-structure
IL6-M82Q7-sds
IL6-M5245 Mouse Mouse IL-6 Protein, His Tag
IL6-M5245-structure
IL6-M5245-sds
IL6-H8218 Human Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity, primary amine labeling
IL6-H8218-structure
IL6-H8218-sds
IL6-H4218 Human Human IL-6 Protein, premium grade
IL6-H4218-structure
IL6-H4218-sds
ACRO Quality

生物活性データの一部

IL6-H8218-Cell-based assay
IL-6 CELL

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).

Protocol
IL6-H4218-Cell-based assay
IL-6 CELL

Human IL-6, premium grade (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of Human IL-6, premium grade is > 1.0ⅹ10^8 IU/mg(QC tested).

Protocol
IL6-H8218-BLI
IL-6 BLI

Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
IL6-C5249-ELISA
IL-6 ELISA

Immobilized Cynomolgus IL-6, His Tag (Cat. No. IL6-C5249) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha, Fc,Avitag (Cat. No. ILR-H82F9) with a linear range of 0.6-39 ng/mL (QC tested).

Protocol

Synonym Name

IL6,Interleukin-6,BSF2,HSF,IFNB2

Background

Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and  IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor  and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Luminol sodium MP-1032 Approved Selvim, Metrio Psoriasis; Immune System Diseases null 1997-01-01 Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis Details
Pomalidomide IMID-4047; CDC-394; CC-4047; IMiD-1 Approved Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 United States Multiple Myeloma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2013-02-08 Pulmonary Fibrosis; Anemia, Sickle Cell; Atypical Squamous Cells of the Cervix; Neurofibromatosis 1; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Glioma; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Sarcoma; Prostatic Neoplasms; Thrombocytosis; Lung Diseases, Interstitial; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Scleroderma, Systemic; Pancreatic Neoplasms; Kidney Diseases; Immunoglobulin Light-chain Amyloidosis; Graft vs Host Disease; Myeloproliferative Disorders; Plasmacytoma; Polycythemia Vera; Medulloblastoma; Bone Marrow Neoplasms Details
Siltuximab cCLB-8; CNTO-328 Approved Johnson & Johnson Sylvant United States Multicentric Castleman's Disease (MCD) Beigene (Beijing) Biotechnology Co Ltd 2014-04-23 Immunoglobulin Light-chain Amyloidosis; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lung Neoplasms; Primary Myelofibrosis; Colorectal Neoplasms; Castleman Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Kidney Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Psychotic Disorders; Polycythemia Vera; Carcinoma, Renal Cell; Schizophrenia; Diabetes Mellitus, Type 1; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Bone Marrow Neoplasms Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; Details
Lenalidomide IMID-5013; CDC-5013; CDC-501; CC-5013; IMiD-3; ENMD-0997; STAR-LLD Approved Celgene Corp Leavdo, Revimid (former Brand Name), 瑞复美, Revlimid United States Myelodysplastic Syndromes Celgene Corp 2005-12-27 Liver Neoplasms; Hematologic Diseases; Optic Nerve Glioma; Leukemia, Myeloid; Immunoproliferative Small Intestinal Disease; Leukemia; Leukemia, Erythroblastic, Acute; Ependymoma; Lymphoma, T-Cell, Peripheral; Solid tumours; Kidney Neoplasms; Lymphoma, B-Cell, Marginal Zone; Bone Marrow Neoplasms; Ovarian Neoplasms; Medulloblastoma; Intestinal Neoplasms; Leukemia, Promyelocytic, Acute; HIV Infections; Anemia; Plaque, Amyloid; Rhabdoid Tumor; Leukemia, Hairy Cell; Pain; Paraproteinemias; Anemia, Refractory, with Excess of Blasts; Polycythemia Vera; Lymphoma, Large B-Cell, Diffuse; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Neoplasms; Nerve Degeneration; Glioblastoma; Plasmacytoma; Hodgkin Disease; Lymphomatoid Granulomatosis; Blood Protein Disorders; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Anemia, Refractory; Graft vs Host Disease; Leukemia, Myelomonocytic, Acute; Myeloproliferative Disorders; Hypothalamic Neoplasms; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Leukemia, Mega Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation Details
MEDI-5117 WBP-216; MEDI-5117 Phase 1 Clinical Wuxi Apptec Co Ltd, Medimmune Arthritis, Rheumatoid Details
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Swiss Biopharma Med GmbH Pyoderma Gangrenosum; Pyoderma Details
FB-704A FB-704; FB-704A Phase 2 Clinical Fountain Biopharma Inc Arthritis, Rheumatoid; Asthma Details
Ensereptide PXL-01 Phase 3 Clinical Promore Pharma Post-surgical adhesions; Tissue Adhesions; Cicatrix Details
Anti-interleukin-6 receptor monoclonal antibody (Biocad) Phase 2 Clinical Biocad Autoimmune Diseases Details
NEX-20A NEX-20A Phase 1 Clinical Nanexa AB Multiple Myeloma Details
Efprezimod alfa CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 Phase 3 Clinical Oncoimmune Inc Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Solid tumours; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma Details
RG-6179 RG-6179 Phase 1 Clinical F. Hoffmann-La Roche Ltd Diabetic macular oedema Details
Olokizumab CDP-6038; Anti-IL6-UCB Phase 3 Clinical Ucb Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis; Crohn Disease Details
Sirukumab BA-003; CNTO-136 Phase 2 Clinical Glaxosmithkline Plc, Janssen Global Services Llc Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lupus Erythematosus, Cutaneous; Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma Details
Wogonin Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University Respiratory Tract Infections; Neoplasms Details
Clazakizumab ALD-518; ALD518-003; BMS-645429; BMS-945429 Phase 3 Clinical Alder Biopharmaceuticals Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis; Kidney Failure, Chronic Details
RO-7200220 RO-7200220 Phase 3 Clinical F. Hoffmann-La Roche Ltd Macular Edema; Diabetic macular oedema Details
Tocilizumab biosimilar (Mycenax Biotech) Phase 1 Clinical Mycenax Biotech Inc Arthritis, Rheumatoid Details
Ziltivekimab COR-001 Phase 3 Clinical Astrazeneca Pharmaceutical Co Ltd Heart Failure; Anemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation; Systemic Inflammatory Response Syndrome Details
Gerilimzumab GB-224; RYI-008; ARGX-109 Phase 1 Clinical Argenx Se Arthritis, Rheumatoid Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒167‐0032
東京都杉並区天沼二丁目７番７号マンション大竹301　

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap